Skip to main content
Log in

Practical Guide for the Treatment of Leishmaniasis

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

This article summarises the clinical features of visceral, cutaneous and mucocutaneous leishmaniasis, and leishmaniasis in HIV-coinfected patients. The characteristics and clinical use of pentavalent antimonials and the traditional drugs used in all forms of leishmaniasis are described. There have been important developments in therapy, such as aminosidine (paromomycin) conventional amphotericin B and lipid-associated amphotericin B. In most cases of leishmaniasis there is a range of treatment options which is determined by the geographical and clinical features. This review is intended to assist the clinician in choosing treatment and in using unfamiliar drugs with safety and efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684–703

    Article  PubMed  CAS  Google Scholar 

  2. Remme JH, De Raadt P, Godai T. The burden of tropical diseases. Med J Aust 1993; 158: 465–9

    PubMed  CAS  Google Scholar 

  3. WHO. Control of the leishmaniases —report of a WHO Expert Committee. Tech Rep Series 793. Geneva: WHO, 1990

    Google Scholar 

  4. Bogdan C, Gessner A, Solbach A, et al. Invasion, control, and persistence of Leishmania parasites. Curr Opin Immunol 1996; 8: 517–25

    Article  PubMed  CAS  Google Scholar 

  5. Bryceson A. Therapy in man. In: Peters W, Killick-Kendrick R, editors. The leishmaniases in biology and medicine. Vol II: clinical aspects and control. London: Academic Press, 1987: 847–95

    Google Scholar 

  6. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46: 296–306

    PubMed  CAS  Google Scholar 

  7. Franco MA, Barbosa AC, Rath S, et al. Antimony oxidation states in antileishmanial drugs. Am J Trop Med Hyg 1995 May; 52(5): 435–7

    PubMed  CAS  Google Scholar 

  8. Berman JD, Edwards N, King M, et al. Biochemistry of Pentostam resistant Leishmania. Am J Trop Med Hyg 1989; 40: 159–64

    PubMed  CAS  Google Scholar 

  9. Gramiccia M, Gradoni L. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of treatment. Ann Trop Med Parasitai 1992; 86: 613–20

    CAS  Google Scholar 

  10. Neal RA, van Bueren J, McCoy NG, et al. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans R Soc Trop Med Hyg 1989 Mar—Apr; 83(2): 197–8

    Article  PubMed  CAS  Google Scholar 

  11. Thakur CP, Kumar M. Observations on the effect of verapamil with sodium stibogluconate in kala azar. Trop Geogr Med 1992; 44: 15–8

    PubMed  CAS  Google Scholar 

  12. Chulay JD, Fleckenstein L, Smith DH. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg 1988; 82(1): 69–72

    Article  PubMed  CAS  Google Scholar 

  13. Al Jaser MA, el Yazigi A, Croft SL. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm Res 1995; 12: 113–6

    Article  PubMed  CAS  Google Scholar 

  14. McBride MO, Linney M, Davidson RN, et al. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin Infect Dis 1995 Sep; 21(3): 710

    Article  PubMed  CAS  Google Scholar 

  15. Sundar S, Sinha PR, Agrawal NDK, et al. A cluster of cases of severe cardiotoxicity among kala azar patients treated with a high osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998 Jul; 59(1): 139–43

    PubMed  CAS  Google Scholar 

  16. Gasser Jr RA, Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994 Jan; 18(1): 83–90

    Article  PubMed  Google Scholar 

  17. Navin TR, Arana B A, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992 Mar; 163(3): 528–34

    Article  Google Scholar 

  18. Hepburn NC, Nolan J, Fenn L, et al. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. Q J Med 1994 Aug; 87(8): 465–72

    CAS  Google Scholar 

  19. Thakur CP, Sinha GP, Pandey AK. Comparison of regimens of amphotericin B deoxycholate in kala-azar. Indian J Med Res 1996; 103: 259–63

    PubMed  CAS  Google Scholar 

  20. Thakur CP, Narain S, Kumar N, et al. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post—kala-azar dermal leishmaniasis. Ann Trop Med Parasitai 1997; 91: 611–6

    Article  CAS  Google Scholar 

  21. De Marie S, Janknegt, Bakker-Woudenberg IA. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33(5): 907–16

    Article  PubMed  Google Scholar 

  22. Thakur CP, Pandey AK, Sinha GP, et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBi-some) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90: 319–22

    Article  PubMed  CAS  Google Scholar 

  23. Davidson RN, di Martino L, Gradoni L, et al. Short course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22: 938–43

    Article  PubMed  CAS  Google Scholar 

  24. Baily GG, Pitt MA, Curry A, et al. Leishmaniasis of the tongue treated with liposomal amphotericin B. J Infect 1994; 28: 327–31

    Article  PubMed  CAS  Google Scholar 

  25. Nonata R, Sampaio R, Marsden PD. Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome. Trans R Soc Trop Med Hyg 1997; 91: 77

    Article  PubMed  CAS  Google Scholar 

  26. Sundar S, Agrawal NK, Sinha PR, et al. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127: 133–7

    PubMed  CAS  Google Scholar 

  27. Jha TK, Olliaro P, Thakur CPN, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316: 1200–5

    Article  PubMed  CAS  Google Scholar 

  28. Sundar S, Singh VP, Sharma S, et al. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 1997; 176: 1117–9

    Article  PubMed  CAS  Google Scholar 

  29. Badaro R, Nascimento C, Carvalho JS, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 1994; 170(2): 413–8

    Article  PubMed  CAS  Google Scholar 

  30. Dogra J, Saxena VN. Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int J Parasitol 1996; 26: 1413–5

    Article  PubMed  CAS  Google Scholar 

  31. Llanos-Cuentas A, Echevarria J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997; 25: 677–84

    Article  PubMed  CAS  Google Scholar 

  32. Soto J, Fuya P, Herrera R, et al. Topical paromomycin/methyl-benzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 1998; 26: 56–8

    Article  PubMed  CAS  Google Scholar 

  33. Sundar S, Reed SG, Singh VP, etal. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1997; 351: 563–5

    Article  Google Scholar 

  34. Magill AJ, Grogl M, Gasser RA, et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328: 1383–7

    Article  PubMed  CAS  Google Scholar 

  35. Davidson RN. AIDS and leishmaniasis. Genitourin Med 1997; 73: 237–9

    PubMed  CAS  Google Scholar 

  36. Gradoni L, Scalone A, Grammiccia M, et al. Epidemiological surveillance of leishmaniasis HIV-1-infected individuals in Italy. AIDS 1996; 10: 785–91

    Article  PubMed  CAS  Google Scholar 

  37. Valasco-Castrejon O, Walton BC, Rivas-Sanchez, et al. Treatment of cutaneous leishmaniasis with localized current field (radiofrequency) in Tabasco, Mexico. Am J Trop Med Hyg 1997; 57(3): 309–12

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert N. Davidson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davidson, R.N. Practical Guide for the Treatment of Leishmaniasis. Drugs 56, 1009–1018 (1998). https://doi.org/10.2165/00003495-199856060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199856060-00005

Keywords

Navigation